-
Publication Venue For
-
Comprehensive review of the research employing the schizophrenia cognition rating scale (SCoRS)..
210:30-38.
2019
-
Evaluation of a plasticity-based cognitive training program in schizophrenia: Results from the eCaesar trial..
208:182-189.
2019
-
The ketogenic diet and remission of psychotic symptoms in schizophrenia: Two case studies..
208:439-440.
2019
-
Attention deficit hyperactivity disorder symptoms as antecedents of later psychotic outcomes in 22q11.2 deletion syndrome..
204:320-325.
2019
-
Basic auditory processing deficits and their association with auditory emotion recognition in schizophrenia..
204:155-161.
2019
-
Factor structure of the positive and negative syndrome scale (PANSS) in people at ultra high risk (UHR) for psychosis..
201:85-90.
2018
-
Polygenic risk score, genome-wide association, and gene set analyses of cognitive domain deficits in schizophrenia..
201:393-399.
2018
-
Genetic correlates of insight in schizophrenia..
195:290-297.
2018
-
The Genetics of Endophenotypes of Neurofunction to Understand Schizophrenia (GENUS) consortium: A collaborative cognitive and neuroimaging genetics project..
195:306-317.
2018
-
Unraveling interrelationships among psychopathology symptoms, cognitive domains and insight dimensions in chronic schizophrenia..
193:83-90.
2018
-
Deviation from expected cognitive ability across psychotic disorders..
192:300-307.
2018
-
Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients..
190:172-179.
2017
-
Self-reported sleep disturbances associated with procedural learning impairment in adolescents at ultra-high risk for psychosis..
190:160-163.
2017
-
Adolescents at clinical-high risk for psychosis: Circadian rhythm disturbances predict worsened prognosis at 1-year follow-up..
189:37-42.
2017
-
Completing the puzzle: The search for pieces in the understanding of psychosis risk in 22q11.2 deletion syndrome..
188:33-34.
2017
-
Validation of the tablet-administered Brief Assessment of Cognition (BAC App)..
181:100-106.
2017
-
Validation of a Computerized test of Functional Capacity..
175:90-96.
2016
-
Impaired hippocampal-dependent memory and reduced parvalbumin-positive interneurons in a ketamine mouse model of schizophrenia..
171:187-194.
2016
-
Unitary construct of generalized cognitive ability underlying BACS performance across psychotic disorders and in their first-degree relatives..
170:156-161.
2016
-
Working memory impairment in probands with schizoaffective disorder and first degree relatives of schizophrenia probands extend beyond deficits predicted by generalized neuropsychological impairment..
166:310-315.
2015
-
A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy..
164:136-142.
2015
-
Actigraphic-measured sleep disturbance predicts increased positive symptoms in adolescents at ultra high-risk for psychosis: A longitudinal study..
164:15-20.
2015
-
Impact of psychiatric comorbidity in individuals at Ultra High Risk of psychosis - Findings from the Longitudinal Youth at Risk Study (LYRIKS)..
164:8-14.
2015
-
Retinal microvessels reflect familial vulnerability to psychotic symptoms: A comparison of twins discordant for psychotic symptoms and controls..
164:47-52.
2015
-
Latent class analysis of discordance between results of drug use assessments in the CATIE data..
161:434-438.
2015
-
The impact of eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: a double-blind, randomized, placebo-controlled trial..
160:180-185.
2014
-
Behavioral response inhibition in psychotic disorders: diagnostic specificity, familiality and relation to generalized cognitive deficit..
159:491-498.
2014
-
Circadian rhythms in cognitive functioning among patients with schizophrenia: impact on signal detection in clinical trials of potential pro-cognitive therapies..
159:205-210.
2014
-
Detecting reliable cognitive change in individual patients with the MATRICS Consensus Cognitive Battery..
159:182-187.
2014
-
The continuous performance test, identical pairs: norms, reliability and performance in healthy controls and patients with schizophrenia in Singapore..
156:233-240.
2014
-
Converting positive and negative symptom scores between PANSS and SAPS/SANS..
152:289-294.
2014
-
Sleep dysfunction and thalamic abnormalities in adolescents at ultra high-risk for psychosis..
151:148-153.
2013
-
Striatal abnormalities and spontaneous dyskinesias in non-clinical psychosis..
151:141-147.
2013
-
The Longitudinal Youth at Risk Study (LYRIKS)--an Asian UHR perspective..
151:279-283.
2013
-
Unraveling the relationship between obesity, schizophrenia and cognition..
151:107-112.
2013
-
Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia..
150:328-333.
2013
-
Social cognition as a mediator between neurocognition and functional outcome in individuals at clinical high risk for psychosis..
150:542-546.
2013
-
Drug and alcohol trajectories among adults with schizophrenia: data from the CATIE study..
148:126-129.
2013
-
Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial..
146:190-195.
2013
-
Interview-based assessment of cognition in schizophrenia: applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care..
146:217-223.
2013
-
Emotion recognition and social/role dysfunction in non-clinical psychosis..
143:70-73.
2013
-
Standardizing the use of the Continuous Performance Test in schizophrenia research: a validation study..
142:153-158.
2012
-
BDNF Val66Met and spontaneous dyskinesias in non-clinical psychosis..
140:65-70.
2012
-
Heritability of functioning in families with schizophrenia in relation to neurocognition..
139:105-109.
2012
-
A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder..
138:35-38.
2012
-
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia..
136:25-31.
2012
-
Insomnia is frequent in schizophrenia and associated with night eating and obesity..
133:238-243.
2011
-
Substance use and schizophrenia: adverse correlates in the CATIE study sample..
132:177-182.
2011
-
Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study..
130:47-52.
2011
-
The association between weight change and symptom reduction in the CATIE schizophrenia trial..
128:166-170.
2011
-
Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone..
127:188-194.
2011
-
The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study..
126:124-131.
2011
-
Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial..
125:161-168.
2011
-
Attention deficits in schizophrenia--preliminary evidence of dissociable transient and sustained deficits..
122:104-112.
2010
-
The Cognitive Assessment Interview (CAI): development and validation of an empirically derived, brief interview-based measure of cognition..
121:24-31.
2010
-
Social functioning in urban, predominantly African American, socially disadvantaged patients with first-episode nonaffective psychosis..
119:95-100.
2010
-
Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial..
116:118-125.
2010
-
The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial..
115:17-23.
2009
-
Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial..
113:12-18.
2009
-
Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study..
111:9-16.
2009
-
Disrupted network cross talk, hippocampal dysfunction and hallucinations in schizophrenia.
2018
-
Cognitive burden of anticholinergic medications in psychotic disorders.
2017
-
Neuropsychological functions of prefrontal cortex are selectively impaired early in the course of schizophrenia